Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-02-13
2010-06-29
Canella, Karen A (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S063000, C436S064000
Reexamination Certificate
active
07745159
ABSTRACT:
The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.
REFERENCES:
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 4612282 (1986-09-01), Schlom et al.
patent: 4713352 (1987-12-01), Bander et al.
patent: 4737579 (1988-04-01), Hellström et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4906562 (1990-03-01), Hellstrom et al.
patent: 5091177 (1992-02-01), Hellström et al.
patent: 5525337 (1996-06-01), Willingham et al.
patent: 5633142 (1997-05-01), Herlyn et al.
patent: 6083502 (2000-07-01), Pastan et al.
patent: WO 97/25068 (1997-07-01), None
Freshney, The Culture of Animal Cells, 1994, p. 5.
Abstract of Bones et al (Tumour Biology, 2003, vol. 23, suppl., p. 41).
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5).
Andrew and Titus, (“Antibody Detection and preparation”, In: Current protocols in Immunology, Margulies et al, Ed.s, 1991, pp. 2.7.1-2.7.7).
Kerr and Thorpe (Immunochemistry LabFax, 1994, p. 175-177.
Kerr and Thorpe (Immunochemistry LabFax, 1994, pp. vii-xi).
Gebauer et al., 1998, Eur. J. Gynaecol. Oncol. 19(4):363-367 (Abstract Only).
Ho-Dac-Pannekeet et al., 1997, Kidney Int. 51(3):888-893 (Abstract Only).
Ho-Dac-Pannekeet et al., 1997, Adv. Peri. Dial. 13:17-22 (Abstract Only).
Kubonishi et al., 1997, Br. J. Haematol 98(2):450-452 (Abstract Only).
Luo et al., 1998, J. Biotechnol. 65(2-3):225-228 (Abstract Only).
Schlebusch et al., 1997, Hybridoma 16(1):47-52 (Abstract Only).
Allum et al., “Monoclonal Antibodies in the Diagnosis and Treatment of Malignant Conditions,”Surgery Annual 18:41-64, 1986.
Bast et al., “A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer,”New England J. of Medicine 309(14):883-887, 1983.
Bell et al., “The Performance of Screening Tests for Ovarian Cancer: Results of a Systematic Review,”British J. of Obstetrics and Gynaecology 105(11):1136-1147, 1998.
Blumenthal, R. et al., “Physiological Factors Influencing Radioantibody Uptake: a Study of Four Human Colonic Carcinomas,”Int J Cancer 51(6):935-41, Jul. 1992.
Chang and Pastan, “Molecular Cloning and Expression of a cDNA Encoding a Protein Detected by the K1 Antibody from an Ovarian Carcinoma (Ovcar-3) Cell Line,”Int. J. Cancer 57:90-97, 1994.
Chang and Pastan, “Molecular Cloning of Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas, and Ovarian Cancers,”Proc. Natl. Acad. Sci. USA 93:136-140, 1996.
Chang et al., “Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium,”Cancer Research 52(1):181-186, 1992.
Chang et al., “Frequent Expression of the Tumor Antigen CAK1 in Squamous-Cell Carcinomas,”Int. J. Cancer 51(4):548-554, 1992.
Chang et al., “Isolation and Characterization of a Monoclonal Antibody, K1, Reactive With Ovarian Cancers and Normal Mesothelium,”Int. J Cancer 50(3):373-381, 1992.
Chang, K. et al., “Monoclonal Antibody K1 Reacts with Epithelial Mesothelioma but not with Lung Adenocarcinoma,”Am J Surg Pathol.16(3):259-68, Mar. 1992.
Chowdhury et al., “Isolation of a High-Affinity Stable Single-Chain Fv Specific for Mesothelin From DNA-Immunized Mice by Phage Display and Construction of a Recombinant Immunotoxin With Anti-Tumor Activity,”Proc. Natl. Acad. Sci. USA 95(2):669-674, 1998.
Cioffi et al., “OVCA (CA 125) Second Generation: Technical Aspects and Serum Levels in Controls, Patients With Liver Disease, Pregnant Women and Patients With Ovarian Disease,”Tumori 83(2):594-598, 1997.
Emery and Harris, “Strategies for Humaniing Antibodies,” in Antibody Engineering, 2ndEd., C. Borrebaeck, ed., 1995, pp. 159-160.
Fink and Clarke, “Monoclonal Antibodies as Diagnostic Reagents for the Identification and Characterization of Human Tumor Antigens,” inProgress in Clinical Pathology, Grune & Stratton, Inc., New York, 1984, Chap. 6, vol. IX, pp. 121-133.
Gebauer and Müller-Ruchholtz, “Tumor Marker Concentrations in Normal and Malignant Tissues of Colorectal Cancer Patients and their Prognostic Relevance,”Anticancer Research 17(4B):2939-2942, 1997.
Hellström et al., “Highly Tumor-Reactive, Internalizing, Mouse Monoclonal Antibodies to Ley-Related Cell Surface Antigens,”Cancer Research 50(7):2183-2190, 1990.
Hellström et al., “Monoclonal Antibodies Raised Against Human Lung Carcinoma,”Cancer Research 46(8):3917-3923, 1986.
Hirokawa et al., “Neuroblastoma in an Adult with a High Serum Level of Carbohydrate Antigen, CA125: Report of a Case,”Surgery Today28:349-354, 1998.
Hollenbaugh et al., “Cleavable CD40Ig Fusion Proteins and the Binding to sgp39,”J. of Immunological Methods 188:1-7, 1995.
Ind et al., “Serum Concentrations of Cancer Antigen 125, Placental Alkaline Phosphatase, Cancer-Associated Serum Antigen and Free Beta Human Chorionic Gonadotrophin as Prognostic Markers for Epithelial Ovarian Cancer,”British J. of Obstetrics and Gynaecology 104(9):1024-1029, 1997.
Jäger et al., “Humoral Immune Responses of Cancer Patients against ‘Cancer-Testis’ Antigent NY-ESO-1: Correlation with Clinical Events,”Int. J. Cancer(Pred. Oncol.)84:506-510, 1999.
Johnston, “Applications of Monoclonal Antibodies in Clinical Cytology as Exemplified by Studies With Monoclonal Antibody B72.3,”J. of Clinical Cytology and Cytopathology 31(5):537-556, 1987.
Kabawat, S. et al., “Tissue Distribution of a Coelomic-Epithelium-Related Antigen Recognized by the Monoclonal Antibody OC125,”Int J Gynecol Pathol. 2(3):275-85, 1983.
Kaplan et al., Clinical Chemistry (textbook), p. 44, 1984.
Kerr and Thorpe, “Purified antibodies” and “Biotinylation of Proteins,”Immunochemistry LabFax, p. 20 and pp. 164-165, 1994.
Kerr and Thorpe,Immunochemistry LabFax, pp. 175-177 and 202-203, 1994.
Klein, J., “Self-nonself Discrimination, Histoincompatibility, and the Concept of Immunology,”Immunogenetics 50(3-4):116-23, Nov. 1999.
Kohno et al. “Compositional Bias and Mimicry Toward the Nonself Proteome in Immunodominant T Cell Epitopes of Self and Nonself Antigens,”FASEB 14, pp. 431-438, 2000.
Kojima et al., “Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA,”J. of Biological Chemistry 270(37):21984-21990, 1995.
Kudoh et al., “Preoperative Determination of Several Serum Tumor Markers in Patients With Primary Epithelial Ovarian Carcinoma,”Gynecol. Obstet. Invest. 47(1):52-57, 1999.
Kuroki et al., “Reducing Interference from Heterophilic Antibodies in a Two-site Immunoassay for Carcinoembryonic Antigen (CEA) by using a Human/Mouse Chimeric Antibody to CEA as the Tracer,”J. Immunological Methods 180:81-91, 1995.
Lake et al., “Natural and Induced Human Antibody Response to Cancer,”Cancer Investigation 18(5):480-489, 2000.
Lloyd et al., “Isolation and Characterization of Ovarian Cancer Antigen CA 125 Using a New Monoclonal Antibody (VK-8): Identification As a Mucin-type Molecule,”Int. J. Cancer 71(5):842-850, 1997.
Meier et al., “CA125 Based Diagnosis and Therapy in Recurrent Ovarian Cancer
Hellstrom Ingegerd
Hellstrom Karl Erik
Scholler Nathalie B
LandOfFree
Methods and compositions for diagnosing carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for diagnosing carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for diagnosing carcinomas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154203